RESUMO
BACKGROUND: We explored the combination of rilpivirine plus cobicistat-boosted darunavir [a two-drug regimen (2DR)] when switching from standard triple combined ART. METHODS: In this randomized, open-label, non-inferiority trial, participants had an HIV-RNA <50â copies/mL on a stable (>6â months) three-drug regimen. The primary endpoint was proportion with HIV-RNA <50â copies/mL at Week 24 (snapshot algorithm), with a -12% non-inferiority margin. ClinicalTrials.gov: NCT04064632. RESULTS: One hundred and sixty patients were allocated (1:1) to 2DR or to continue current ART (CAR). At Week 24, 72 (90.0%) of participants with 2DR and 75 (93.8%) with CAR maintained HIV-RNA <50â copies/mL [difference -3.75% (95% CI = -11.63 to 5.63)], confirming non-inferiority. Non-inferiority was confirmed considering an HIV-RNA >50â copies/mL (0% for 2DR; 3.7% for CAR; 95% CI = -0.4 to 7.9). Four patients reported adverse events not leading to treatment discontinuation (one patient in the 2DR group and three patients in the CAR group); eight subjects discontinued therapy in the 2DR group and three in the CAR group. With 2DR, lipid serum concentrations increased, but differences were statistically significant only for tenofovir disoproxil fumarate-containing CAR and in 2DR patients receiving a pre-switch regimen including tenofovir disoproxil fumarate. Median bone stiffness decreased in the CAR group from 86.1â g/cm2 (IQR = 74-98) to 83.2â g/cm2 (IQR = 74-97) and increased in the 2DR group from 84.9â g/cm2 (IQR = 74-103) to 85.5â g/cm2 (IQR = 74-101). The reduction within the CAR group was significant (P = 0.043). CONCLUSIONS: Once-daily rilpivirine plus cobicistat-boosted darunavir is an effective 2DR that combines a high virological efficacy with a potential to avoid major NRTI toxicities.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , HIV-1 , Preparações Farmacêuticas , Adenina/uso terapêutico , Fármacos Anti-HIV/efeitos adversos , Cobicistat/uso terapêutico , Darunavir/efeitos adversos , Emtricitabina/uso terapêutico , Infecções por HIV/tratamento farmacológico , Humanos , Rilpivirina/uso terapêutico , Resultado do Tratamento , Carga ViralRESUMO
BACKGROUND: The limb girdle muscular dystrophies (LGMD) are a heterogeneous group of Mendelian disorders highlighted by weakness of the pelvic and shoulder girdle muscles. Seventeen autosomal loci have been so far identified and genetic tests are mandatory to distinguish among the forms. Mutations at the calpain 3 locus (CAPN3) cause LGMD type 2A. OBJECTIVE: To obtain unbiased information on the consequences of CAPN3 mutations. PATIENTS: 530 subjects with different grades of symptoms and 300 controls. METHODS: High throughput denaturing HPLC analysis of DNA pools. RESULTS: 141 LGMD2A cases were identified, carrying 82 different CAPN3 mutations (45 novel), along with 18 novel polymorphisms/variants. Females had a more favourable course than males. In 94% of the more severely affected patient group, the defect was also discovered in the second allele. This proves the sensitivity of the approach. CAPN3 mutations were found in 35.1% of classical LGMD phenotypes. Mutations were also found in 18.4% of atypical patients and in 12.6% of subjects with high serum creatine kinase levels. CONCLUSIONS: A non-invasive and cost-effective strategy, based on the high throughput denaturing HPLC analysis of DNA pools, was used to obtain unbiased information on the consequences of CAPN3 mutations in the largest genetic study ever undertaken. This broadens the spectrum of LGMD2A phenotypes and sets the carrier frequency at 1:103.
Assuntos
Calpaína/genética , Testes Genéticos/métodos , Proteínas Musculares/genética , Distrofia Muscular do Cíngulo dos Membros/genética , Fenótipo , Adulto , Cromatografia Líquida de Alta Pressão/métodos , Estudos de Coortes , DNA/sangue , DNA/metabolismo , Feminino , Genes Recessivos , Humanos , Masculino , Mutação , Polimorfismo GenéticoRESUMO
The authors have been treating heart involvement in muscle dystrophy since 1978. However, this study aimed to define recent therapeutic protocols, evaluating the results of cardiac treatment, performed between 1st February 2004 and 31st July, 2006. In this period, 100 Becker, 136 Duchenne, 44 Limb-girdle and 116 Steinert patients were treated. In that same period, a large group of MD patients refusing cardiac therapy have also been followed. All patients had previously been classified in the appropriate stage of cardiomyopathy and examined at least twice every year and even every week if presenting heart failure. The results show the usefulness of the recent protocols of treatment of cardiac involvement in muscle dystrophy patients.
Assuntos
Baixo Débito Cardíaco/tratamento farmacológico , Baixo Débito Cardíaco/etiologia , Distrofia Muscular do Cíngulo dos Membros/complicações , Distrofia Muscular de Duchenne/complicações , Distrofia Miotônica/complicações , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Estudos de Casos e Controles , Progressão da Doença , Fosinopril/uso terapêutico , Furosemida/uso terapêutico , Humanos , Pregnenodionas/uso terapêutico , Prognóstico , Estudos Retrospectivos , Índice de Gravidade de Doença , Inibidores de Simportadores de Cloreto de Sódio e Potássio/uso terapêuticoAssuntos
Algoritmos , Densidade Óssea/fisiologia , Osso e Ossos/metabolismo , Fraturas Ósseas/epidemiologia , Infecções por HIV/complicações , Fraturas Ósseas/prevenção & controle , Soropositividade para HIV/complicações , Humanos , Programas de Rastreamento , Probabilidade , Fatores de Risco , Sensibilidade e EspecificidadeRESUMO
European guidelines recommend the routine offer of an HIV test in patients with a number of AIDS-defining and non-AIDS conditions believed to share an association with HIV; so called indicator conditions (IC). Adherence with this guidance across Europe is not known. We audited HIV testing behaviour in patients accessing care for a number of ICs. Participating centres reviewed the case notes of either 100 patients or of all consecutive patients in one year, presenting for each of the following ICs: tuberculosis, non-Hodgkins lymphoma, anal and cervical cancer, hepatitis B and C and oesophageal candidiasis. Observed HIV-positive rates were applied by region and IC to estimate the number of HIV diagnoses potentially missed. Outcomes examined were: HIV test rate (% of total patients with IC), HIV test accepted (% of tests performed/% of tests offered) and new HIV diagnosis rate (%). There were 49 audits from 23 centres, representing 7037 patients. The median test rate across audits was 72% (IQR 32-97), lowest in Northern Europe (median 44%, IQR 22-68%) and highest in Eastern Europe (median 99%, IQR 86-100). Uptake of testing was close to 100% in all regions. The median HIV+ rate was 0.9% (IQR 0.0-4.9), with 29 audits (60.4%) having an HIV+ rate >0.1%. After adjustment, there were no differences between regions of Europe in the proportion with >0.1% testing positive (global p = 0.14). A total of 113 patients tested HIV+. Applying the observed rates of testing HIV+ within individual ICs and regions to all persons presenting with an IC suggested that 105 diagnoses were potentially missed. Testing rates in well-established HIV ICs remained low across Europe, despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and care. Significant numbers may have had an opportunity for HIV diagnosis if all persons included in IC audits had been tested.
Assuntos
Sorodiagnóstico da AIDS/estatística & dados numéricos , Guias como Assunto , Europa (Continente)/epidemiologia , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Humanos , Estudos RetrospectivosRESUMO
The correlations between the type of gene mutation and the cardiac clinical picture were examined in 284 patients with dystrophinopathy (200 Duchenne and 84 Becker). The subjects with normal heart showed deletions including exons 48-49 in 21.4% DMD and in 25% BMD, and other deletions in 35.7% DMD and 25% BMD; vice versa the cases with severe cardiac involvement showed deletions including 48-49 in 38.8% DMD and 37.5% BMD and other deletions in 32.9% DMD and 20% BMD. The age of death was 18 years in DMD patients with deletions including 48-49 whereas the age was about 22 in the cases with other deletions. The differences were statistically significant.
Assuntos
Cardiomiopatias/genética , Distrofina/genética , Genes , Mutação , Adolescente , Adulto , Idoso , Cardiomiopatias/diagnóstico , Cardiomiopatias/diagnóstico por imagem , Criança , Pré-Escolar , Ecocardiografia , Eletrocardiografia , Deleção de Genes , Genótipo , Humanos , Pessoa de Meia-Idade , Distrofias Musculares/classificação , Distrofias Musculares/genética , Fenótipo , Análise de SobrevidaRESUMO
We compare the long-term benefits and side effects of deflazacort using two treatment protocols from Naples (N) and Toronto (T). Boys with Duchenne muscular dystrophy between the ages of 8 and 15 years and who had four or more years of deflazacort treatment were reviewed. Diagnostic criteria included males with proximal muscle weakness evident before 5 years, increased serum creatine kinase and genetic testing and/or a muscle biopsy consistent with Duchenne muscular dystrophy. Thirty-seven boys were treated with protocol-N using deflazacort at a dose of 0.6 mg/kg per day for the first 20 days of the month and no deflazacort for the remainder of the month. Boys with osteoporosis received daily vitamin D and calcium. Deflazacort treatment started between 4 and 8 years of age. Thirty-two were treated with protocol-T using deflazacort at a dose of 0.9 mg/kg per day, plus daily vitamin D and calcium. Treatment started between 6 and 8 years of age. All boys were monitored every 4-6 months. The results were compared with age-matched controls in the two groups (19 for protocol-N and 30 for protocol-T). For the boys treated with protocol-N, 97% were ambulatory at 9 years (control, 22%), 35% at 12 years (control, 0%), 25% at 15 years (control, 0%). For the 32 boys treated with protocol-T, 100% were ambulatory at 9 years (control, 48%), 83% at 12 years (control, 0%) and 77% at 15 years (control, 0%). No aids or leg braces were used for ambulation. In boys 13 years and older, a scoliosis of >20 degrees developed in 30% of the boys on protocol-N, 16% on protocol-T and 90% of controls. For protocol-N, no cataracts were observed while in protocol-T, 30% of boys had asymptomatic cataracts that required no treatment. Fractures occurred in 19% (control 16%) of boys on protocol-N and 16% (control, 20%) of boys on protocol-T. This report illustrates: (a) the importance of collaborative studies in developing treatment protocols in Duchenne muscular dystrophy and (b) the long-term beneficial effects of deflazacort treatment in both protocols. However, the protocol-T seems to be more effective and frequently is associated with asymptomatic cataracts.
Assuntos
Protocolos Clínicos , Imunossupressores/uso terapêutico , Distrofia Muscular de Duchenne/tratamento farmacológico , Pregnenodionas/uso terapêutico , Adolescente , Estatura/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Cálcio/uso terapêutico , Estudos de Casos e Controles , Catarata/induzido quimicamente , Criança , Suplementos Nutricionais , Esquema de Medicação , Seguimentos , Fraturas Ósseas/induzido quimicamente , Humanos , Imunossupressores/efeitos adversos , Masculino , Atividade Motora/efeitos dos fármacos , Pregnenodionas/efeitos adversos , Desempenho Psicomotor/efeitos dos fármacos , Escoliose/induzido quimicamente , Resultado do Tratamento , Vitamina D/uso terapêuticoRESUMO
Sarcoglycanopathies constitute a subgroup of limb-girdle recessive muscular dystrophies due to defects in sarcoglycan complex that comprises five distinct transmembrane proteins called alpha-, beta-, gamma-, delta-and epsilon-sarcoglycans. As it is well known that sarcoglycans are expressed both in heart and in skeletal muscles and a complete deficiency in delta-sarcoglycan is the cause of the Syrian hamster BIO.14 cardiomyopathy, we studied cardiac and respiratory involvement in 20 patients with sarcoglycanopathies by clinical, electrocardiographic, echocardiographic, scintigraphic and spirometric assessments. A normal heart function was found in 31.3% of all patients; a preclinical cardiomyopathy in 43.7%; an arrhythmogenic cardiomyopathy in 6.3% and initial signs of dilated cardiomyopathy in 18.7%. In one patient the data were examined retrospectively. No correlation was found between cardiac and skeletal muscle involvement. With reference to the type of sarcoglycanopathy, signs of hypoxic myocardial damage occurred in beta-, gamma- and delta-sarcoglycanopathies, while initial signs of a dilated cardiomyopathy in gamma- and delta-sarcoglycanopathies were found. A normal respiratory function was observed in 23.5% of all patients, a mild impairment in 35.4%, a moderate impairment in 29.4%, and a severe impairment in 11.7%.
Assuntos
Cardiomiopatias/fisiopatologia , Proteínas do Citoesqueleto/genética , Glicoproteínas de Membrana/genética , Distrofias Musculares/fisiopatologia , Mutação/genética , Insuficiência Respiratória/fisiopatologia , Adolescente , Adulto , Cardiomiopatias/genética , Cardiomiopatias/patologia , Criança , Pré-Escolar , Proteínas do Citoesqueleto/metabolismo , Análise Mutacional de DNA , Feminino , Humanos , Imuno-Histoquímica , Masculino , Glicoproteínas de Membrana/metabolismo , Pessoa de Meia-Idade , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Distrofias Musculares/diagnóstico por imagem , Distrofias Musculares/genética , Miocárdio/metabolismo , Miocárdio/patologia , Fenótipo , Testes de Função Respiratória , Insuficiência Respiratória/genética , Insuficiência Respiratória/patologia , Sarcoglicanas , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
To assess the incidence, nature and evolution of cardiac disease in Duchenne muscular dystrophy, 328 patients were studied between 1976 and 1987 for periods varying from 3 to 11 years. Patients underwent regular clinical examination, electrocardiography, echocardiography and radiological assessment. Pre-clinical cardiac involvement was found in 25% of patients under 6 years old increasing to 59% between the ages of 6 and 10 years and then declining in incidence with age. Clinically apparent cardiomyopathy is first evident after 10 years of age and increases in incidence with age, being present in all patients over 18 years of age. Its clinical impact is discussed.
Assuntos
Cardiomiopatias/epidemiologia , Distrofias Musculares/complicações , Adolescente , Cardiomiopatias/fisiopatologia , Cardiomiopatia Dilatada/epidemiologia , Criança , Pré-Escolar , Eletrocardiografia , Seguimentos , Bloqueio Cardíaco/epidemiologia , Humanos , Incidência , Vértebras Lombares , Distrofias Musculares/fisiopatologia , Transtornos Respiratórios/fisiopatologia , Doenças da Coluna Vertebral/fisiopatologia , Vértebras TorácicasRESUMO
Clinical, electrocardiographic, echocardiographic and other instrumental examinations were performed on 233 persons primarily seeking genetic advice about the Duchenne/Becker gene in order to reveal the incidence of dystrophic cardiomyopathy in a population of females with a close relationship with patients suffering from Duchenne or Becker muscular dystrophy. Among these consultands, 210 were Duchenne and 23 Becker. Eight five (40.4%) Duchenne and 8 (34.8%) Becker consultands showed a normal cardiac status; 35 (16.6%) Duchenne and 6 (26.1%) Becker had clinically evident cardiomyopathy; 90 (43%) Duchenne and 9 (39.1%) Becker showed minor signs of myocardial involvement. The link between myocardial involvement and the Duchenne/Becker carrier condition was demonstrated through the observation that the percentage of cases showing pre-clinical or clinically evident cardiomyopathy was higher in the consultands with pathological values of serum creatine kinase activity (obligatory carriers) and/or an estimated genetic risk higher than 70% than in the consultands showing a normal value of serum creatine kinase activity (less than 80 U/l) and/or a genetic risk lower than 70%.
Assuntos
Cardiomiopatias/genética , Distrofias Musculares/genética , Adolescente , Adulto , Cardiomiopatias/diagnóstico por imagem , Cardiomiopatia Hipertrófica/genética , Criança , Pré-Escolar , Ecocardiografia , Eletrocardiografia , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
We evaluated the arrhythmic profile in a population of 20 Becker muscular dystrophy (BMD) patients searching for possible correlations between the severity of the arrhythmic events, the cardiac autonomic balance (assessed by heart rate variability analysis in the time domain) and the degree of left ventricular systolic impairment. A population of 14 male healthy individuals served as the control group. BMD subjects exhibited lower values of SDNN (P=0.013), SDANN index (P=0.008) and 24-h mean heart rate (P=0.002). The total number of premature ventricular beats (totPVB) and the number of PVB out of 1000 heartbeats (PVB/1000) appeared also higher in BMD subjects (P=0.05 and P=0.046, respectively). No difference was found in terms of 24-h mean QTc and 24-h longest QT among the two groups. TotPVB and PVB/1000 were inversely related to both the ejection fraction (r= -0.620, P=0.004 and r= -0.517, P=0.019) and to the shortening fraction (r= -0.568, P=0.009 and r= -0.469, P=0.037). Twenty-four-h mean QTc was also inversely related to both the ejection fraction (r= -0.520, P=0.019) and the fractional shortening (r= -0.491, P=0.028). These data suggest that in BMD there is cardiac autonomic imbalance characterized by sympathetic predominance and an increased susceptibility to ventricular arrhythmias, even in the absence of overt cardiomyopathy. Furthermore, the severity of the arrhythmic profile in BMD appears closely related to the degree of left ventricular systolic dysfunction.
Assuntos
Sistema Nervoso Autônomo/fisiopatologia , Ventrículos do Coração/inervação , Distrofias Musculares/complicações , Taquicardia Ventricular/complicações , Disfunção Ventricular Esquerda/etiologia , Adulto , DNA/análise , Distrofina/genética , Ecocardiografia , Eletrocardiografia Ambulatorial , Frequência Cardíaca , Ventrículos do Coração/fisiopatologia , Humanos , Masculino , Distrofias Musculares/diagnóstico , Distrofias Musculares/metabolismo , Reação em Cadeia da Polimerase , Prognóstico , Estudos Prospectivos , Volume Sistólico , Sístole , Taquicardia Ventricular/diagnóstico por imagem , Taquicardia Ventricular/fisiopatologia , Nervo Vago/fisiopatologia , Disfunção Ventricular Esquerda/diagnóstico por imagem , Disfunção Ventricular Esquerda/fisiopatologiaRESUMO
Aim of the study was to investigate whether the administration of gentamicin could restore dystrophin expression in striated muscles of patients with Duchenne muscular dystrophy caused by premature stop codon, as reported in mdx mice. Four Duchenne patients, still ambulant or in wheelchair stage for less than 4 months, selected among those with point mutations resulting in premature stop codons, received two 6-day cycles of gentamicin sulfate, at an interval of 7 weeks, according to the protocol approved by the Ethics Committee of the Second University of Naples. A muscle biopsy was performed after the second cycle of administration; the specimens were analysed by both immuno-histochemistry and Western blotting. Skeletal muscle changes were monitored by dynamic tests and Creatine Kinase values; at the beginning and end of treatment, cardiac and respiratory status was evaluated by electrocardiography, echocardiography, acoustic densitometry and vital capacity. Side-effects such as nephrotoxicity and ototoxicity were also monitored. Three out of four patients, who had the most permissive UGA as stop codon, showed positive results. In one patient, there was a dramatic re-expression of dystrophin by both immuno-histochemistry and Western blot; in two patients, dystrophin positive fibres were seen by the antibody to the rod domain with immuno-histochemistry; the fourth patient, with UAA as stop codon, showed no expression of dystrophin at all. These results suggest that gentamicin is able to recover dystrophin expression in a subset of Duchenne patients with nonsense mutations, raising the possibility of the first pharmacological treatment for muscular dystrophy.
Assuntos
Antibacterianos/uso terapêutico , Códon sem Sentido/efeitos dos fármacos , Códon sem Sentido/genética , Gentamicinas/uso terapêutico , Distrofia Muscular de Duchenne/tratamento farmacológico , Distrofia Muscular de Duchenne/genética , Antibacterianos/administração & dosagem , Criança , Pré-Escolar , Esquema de Medicação , Distrofina/análise , Distrofina/efeitos dos fármacos , Seguimentos , Gentamicinas/administração & dosagem , Humanos , Masculino , Músculo Esquelético/química , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/patologia , Distrofia Muscular de Duchenne/patologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Primary cardiomyopathies have as dominant feature the involvement of heart muscle itself. They are not the result of other diseases and should be defined as diseases of heart muscle not consequent to disorders of other parts of the cardiovascular apparatus. Most of them are consequent to genetic defects and can be subdivided into three major groups: isolated, associated with skeletal muscle diseases, associated with neurological disorders. Primary cardiomyopathies show an evolution from mild to more severe stages. Four types of cardiomyopathies are classically described: dilated, hypertrophic, restrictive and arrhythmogenic. However, from a clinical point of view, it is possible to distinguish seven stages: pre-clinical, prevalently arrhythmogenic, prevalently pseudo-hypertrophic, spotty fibrotic, restrictive, dilated and refractory heart failure. In the course of their evolution, cardiomyopathies can shift from a clinical picture to another, consequently requiring frequent examinations of patients in order to adjust their treatment.
Assuntos
Cardiomiopatias/classificação , Cardiomiopatias/diagnóstico , Comorbidade , Diagnóstico Diferencial , HumanosRESUMO
An electrocardiographic pattern resembling myocardial infarction is a rare condition in Duchenne muscular dystrophy. We report the case of a Duchenne boy, aged 12 years and 7 month, who, during a programmed examination, showed electrocardiographic signs of ST segment elevation, without symptoms usually accompanying myocardial infarction (chest pain, dyspnoea, sweating). The biological markers of myocardial damage became positive on the 2nd day and recovered on the 5th day. Clinical features of this uncommon pattern are described, with the retrospective evaluation of similar cases from personal records. The differential diagnosis between myocardial necrosis and apoptosis is discussed.
Assuntos
Apoptose/fisiologia , Cardiomiopatias/patologia , Cardiomiopatias/fisiopatologia , Distrofia Muscular de Duchenne/patologia , Distrofia Muscular de Duchenne/fisiopatologia , Infarto do Miocárdio/patologia , Infarto do Miocárdio/fisiopatologia , Necrose , Cardiomiopatias/etiologia , Criança , Diagnóstico Diferencial , Eletrocardiografia , Humanos , Masculino , Distrofia Muscular de Duchenne/complicações , Infarto do Miocárdio/etiologiaRESUMO
Nephrogenic adenoma is an uncommon benign lesion of the urinary tract, that histologically is characterised by glandular-like aspects resembling the distal part of the nephron. It is usually associated with antecedent inflammation, surgical procedures or other injuries. Personal experience with one additional case nephrogenic adenoma of the bladder in a patient with urinary tract tuberculosis is presented.
Assuntos
Bacteriúria/complicações , Mesonefroma/complicações , Tuberculose Urogenital/complicações , Neoplasias da Bexiga Urinária/complicações , Humanos , Hospedeiro Imunocomprometido , Masculino , Mesonefroma/diagnóstico , Mesonefroma/epidemiologia , Mesonefroma/etiologia , Metaplasia , Pessoa de Meia-Idade , Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/diagnóstico , Neoplasias da Bexiga Urinária/epidemiologia , Neoplasias da Bexiga Urinária/etiologiaRESUMO
A new spectrophotometric method for determination of creatine and creatinine values, and hence calculation of the creatine index, is reported. Micropipetting of fingerprick quantities (0.3 ml) of blood enables values to be obtained from obese and progressive muscular dystrophy subjects, whose veins are difficult to find without damaging the tissues.
Assuntos
Creatina/sangue , Distrofias Musculares/sangue , Adolescente , Adulto , Centrifugação , Criança , Pré-Escolar , Creatinina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distrofias Musculares/complicações , Obesidade/complicaçõesRESUMO
After discussing the diagnostic approach to benign tumours of the stomach on the basis of the most valid classifications in literature, the Authors describe the symptoms and frequency of these tumours. They then report 12 personally observed cases, and in particular one case of neurofibroma of the gastric fundus, which was exceptional for localisation, volume and clinical course. They conclude that only open extemporaneous surgical examination can provide confirmation of the benign nature of the neoformation. Therapy must in any case be surgical: the extent of removal will be governed by the extent and location of the tumour, and by the outcome of the histological examination.